[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"venous-embolism\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:venous-embolism":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100600797","cleaner-long-term-assessment-registry---venous-insights-and-efficacy-with-extended-tracking-100600797",false,"NCT07102160","Cleaner Long-tErm Assessment Registry - Venous Insights and Efficacy With eXtended Tracking","A Prospective, Multi-Center, Open-Label Clinical Investigation of the Cleaner Vac® Thrombectomy System for Treatment of Lower Extremity Proximal Deep Vein Thrombosis (DVT)","CLEAR-VIEW XT","Inclusion Criteria:\n\nParticipants must meet all the following criteria to be eligible for the study:\n\n1. At least 18 years of age at the time of consent.\n2. Undergo frontline (primary) treatment with Cleaner Vac® Thrombectomy System in the peripheral venous vasculature and have at least one component introduced into the body.\n3. Written informed consent obtained through the IRB-approved ICF.\n\n   For the DVT cohort, participants must meet all criteria above and below to be eligible for the study:\n4. Present with unilateral or bilateral lower extremity DVT involving at least one of the following veins:\n\n   1. Femoral-popliteal vein\n   2. Common femoral vein\n   3. Iliac vein\n   4. Inferior Vena Cava (IVC)\n5. DVT diagnosis confirmed by imaging within 14 days of the index procedure.\n6. Symptomatic DVT with onset within 6 weeks of enrollment.\n\nExclusion Criteria:\n\nSubjects will be excluded from the study if any of the following criteria are met:\n\n1. Contraindication to systemic or therapeutic doses of anticoagulants.\n2. Contraindication to iodinated contrast that cannot be adequately premedicated.\n3. Life expectancy less than 1 year due to advanced malignancy, as determined by the investigator at the time of enrollment\n4. Patients that are pregnant.\n5. Known coagulation disorders both acquired (Heparin Induced Thrombocytopenia, etc.) or genetic (e.g., Factor V Leiden, etc.), thrombophilia, or hypercoagulable states that, in the opinion of the Investigator, cannot be medically managed throughout the study period.\n6. Treatment of target venous segment with thrombolytics within previous 14 days of the index procedure.\n7. Known congenital anatomic anomalies of the inferior vena cava (IVC) or iliac veins.\n8. Known history of a Patent Foramen Ovale (PFO).\n9. Hemoglobin \\\u003C 8.0 g\u002FdL, INR \\> 2.0 before warfarin was started, or platelets \\\u003C 50,000\u002Fµl which cannot be corrected prior to enrollment.\n10. Severe renal impairment (estimated GFR \\\u003C 30 ml\u002Fmin) in patients who are not yet on dialysis. Patients with GFR \\\u003C30 ml\u002Fmin who are already on dialysis can be enrolled.\n11. Patients with intermediate-high risk or high-risk pulmonary embolism (PE) defined as follows:\n\n    1. High-risk PE: Presence of hemodynamic instability, including cardiac arrest, obstructive shock (systolic blood pressure \\\u003C90 mmHg or need for vasopressors with signs of end-organ hypoperfusion), or persistent hypotension (systolic BP \\\u003C90 mmHg or a drop ≥40 mmHg for \\>15 minutes not due to other causes)\n    2. Intermediate-high-risk PE: Hemodynamically stable patients with both right ventricular (RV) dysfunction (on echocardiography or CT) and elevated cardiac biomarkers (e.g., troponin).\n12. Complete infrarenal IVC occlusion.\n13. Chronic non-ambulatory status.\n14. Current enrollment in another investigational device or drug study that may confound the results of this study. Studies requiring extended follow-up for products that were investigational but have since become commercially available are not considered investigational studies.","ALL","18 Years",{"count":20,"type":21},185,"ESTIMATED","OBSERVATIONAL","The primary objective of this clinical investigation is to evaluate the safety and effectiveness of the Cleaner Vac® Thrombectomy System for the treatment of thrombus in patients with lower extremity proximal deep vein thrombosis (DVT). This prospective, multi-center, open-label study will assess clinical outcomes, device performance, and procedural success in a single DVT study cohort.",[25,26,27,28],"Deep Vein Thrombosis (DVT)","Thrombus in the Peripheral Venous Vasculature","Venous Embolism","Thrombus in the Central and Peripheral Circulatory System, Including Saphenous Vein Grafts",[30,25,31,32,33],"Aspiration Thrombectomy","Peripheral VTE","Venous thromboembolism","Percutaneous mechanical thrombectomy","RECRUITING","2026-06-12",{"date":37,"type":38},"2026-06-16","ACTUAL",{"date":40,"type":38},"2026-02-04",{"date":42,"type":21},"2029-06",{"name":44,"class":45},"Argon Medical Devices","INDUSTRY",4,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":56,"conditions":57,"keywords":62,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":82},"100406533","abbott-vascular-medical-device-registry-100406533","NCT04573660","Abbott Vascular Medical Device Registry","AV-MDR","Inclusion Criteria:\n\n1. Subject is at least 18 years of age.\n2. Subject has a planned procedure, or underwent a procedure, that will use\u002Fused one or more Abbott target devices covered in this registry.\n3. Subject is willing and able to comply with, or has already completed, the follow-up schedule specified in this protocol.\n4. Subject must provide written informed consent prior to any clinical investigation-related data collection or be enrolled under an IRB\u002FEC approved waiver of consent.\n\nExclusion Criteria:\n\n1\\. Subject has active symptoms and\u002For a positive test result of COVID-19 or other rapidly spreading novel infectious agent within the prior 2 months of the date of procedure.",{"count":55,"type":21},3784,"The AV-MDR is a prospective, non-randomized, open-label, multi-center registry. The purpose of the AV-MDR study is to proactively collect and evaluate clinical data on the usage of the devices in scope within their intended use with the aim of confirming safety and performance throughout their expected lifetime, ensuring the continued acceptability of identified risks, detecting emerging risks on the basis of factual evidence, ensuring the continued acceptability of the benefit-risk ratio, and identifying possible systematic misuse or off-label usage such that the intended use can be verified as appropriate.",[58,59,60,27,61],"Acute Myocardial Infarction","Restenoses, Coronary","Coronary Artery Lesions","Arterial Embolism",[63,64,65,66,67,68,69,70,71,72],"Coronary and peripheral stents","ABT-CIP-10349","Vascular plugs","Pacing catheters","Measurement and imaging (FFR and OCT)","Peripheral dilatation catheters","Coronary dilatation catheters","Coronary and peripheral guidewires","Vessel closure\u002Fcompression devices","Vascular access introducers","2025-07-01",{"date":75,"type":38},"2025-07-03",{"date":77,"type":38},"2020-10-25",{"date":79,"type":21},"2031-11",{"name":81,"class":45},"Abbott Medical Devices",37]